Abstract 2072P
Background
Oral mucositis is a debilitating condition seen in head and neck cancer(HNC) patients treated by radiotherapy(RT). The aim of study was to evaluate the response of combined new oral agents as local applicant to prevent mucositisand to record the change in mucositis grading during and after RT.
Methods
Sixty threepatients of post-operative HNC planned for adjuvantRT were randomized to treat mucositis by soda bicarbonate gargles only (Control arm: n=30) 4-5 times a day or soda bicarbonate gargle along with new agent comprised of five drugs (ORA-5GEL): one tablespoon each of honey, choline salicylate ointment(8.7w/w), and lignocaine ointment(2%w/w), one tablet of fluconazole 150mg and metronidazole 400mg were mixed to form a paste and applied intraorally starting from 2nd week of RT (Study arm:n=33).
Results
Severity of mucositis was found to be either stable or in downgrading trend after the application of the ORA-5 gel. None of the patients had grade3 mucositis in study arm compared to 15 patients in control arm. Grade 1 mucositis was seen in 64% and 97% of patients at the end of week 3 that progressed to grade 2 in 27% and 70% patients study and control arm, respectively, by the end of 4thweek (p<0.001). On univariate analysis, factors associated with higher mucositis grading were: high disease burden (Stage IV), conventional RT technique and concurrent chemotherapy. In study arm reversible trend of grading was observed in this subset of patients also. With the continuous use of soda bicarbonate gargle and symptomatic treatment, the frequency of grade 3 mucositis in control arm decreased, however, there was significant difference in grading in both the groups till week 7(p<0.001). By the end of the treatment, none of the patients in control arm had grade 0 mucositis compared to 73% in study arm.
Conclusions
ORA-5 GEL effectively acts on all stages of mucositis and prevents not only severity and progression in all patients but also shows reversible grading during RT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
C. Prakash.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06